• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
Citation: YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417

Advances of the uricosuric drugs

More Information
  • Promoting uric acid excretion is an important approach for the treatment of gout and hyperuricemia. There are two main approaches included in the mechanism: one is inhibiting the function of renal tubular uric acid transporter to reduce the absorption of uric acid, and promoting excretion; the other is using uricase to catalyze the oxidation of uric acid to a more water-soluble allantoin that can also increase excretion. The mechanisms and progress of the uricosuric drugs are reviewed in this paper, providing reference for the further research and development.
  • [1]
    Choi HK,Mount DB,Reginato AM,et al.Pathogenesis of gout [J].Ann Intern Med,2005,143(7):499-516.
    [2]
    Kang DH,Nakagawa T,Feng L,et al.A role for uric acid in the progression of renal disease [J].J Am Soc Nephrol,2002,13(12):2888-2897.
    [3]
    De Lau LM,Koudstaal PJ,Hofman A,et al.Serum uric acid levels and the risk of Parkinson disease [J].Ann Neurol,2005,58(5):797-800.
    [4]
    Rizwan AN,Burckhardt G.Organic anion transporters of the SLC22 family:biopharmaceutical,physiological,and pathological roles [J].Pharm Res,2007,24(3):450-470.
    [5]
    Anzai N,Jutabha P,Kanai Y,et al.Integrated physiology of proximal tubular organic anion transport [J].Curr Opin Nephrol Hypertens,2005,14(5):472-479.
    [6]
    Miyazaki H,Anzai N,Ekaratanawong S,et al.Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins [J].J Am Soc Nephrol,2005,16(12):3498-3506.
    [7]
    Burns CM,Wortmann RL.Gout therapeutics:new drugs for an old disease [J].Lancet,2011,377(9760):165-177.
    [8]
    Matsuo H,Nakayama A,Sakiyama M,et al.ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload [J].Sci Rep,2014,4:3755.
    [9]
    Li S,Sanna S,Maschio A,et al.The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts [J].PLoS Genet,2007,3(11):2156-2162.
    [10]
    Preitner F,Bonny O,Laverrière A,et al.Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy [J].Proc Natl Acad Sci U S A,2009,106(36):15501-15506.
    [11]
    Watanabe S,Kanellis J,Nakagawa T,et al.Reducing uric acid as a means to prevent cardiovascular and renal disease [J].Expert Opin Ther Pat,2002,12(2):193-199.
    [12]
    Fleischmann R,Kerr B,Yeh LT,et al.Pharmacodynamic,pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia [J].Rheumatology,2014,53(12):2167-2174.
    [13]
    Tan PK, Hyndman D, Liu S, et al. Lesinurad(RDEA594),a novel investigational uricosuric agent for hyperuricemia and gout,blocks transport of uric acid induced by hydrochlorothiazide[J].Ann Rheum Dis,2011,70(Suppl 3):187.
    [14]
    Miner JN, Tan P. RDEA3170, a novel, high affinity URAT1 inhibitor binds to a central domain within URAT1 [J].Ann Rheum Dis,2013,71(Suppl 3):446 [2015-07-14] .doi: 10.1136/annrheumdis-2012-eular.2846.
    [15]
    Ahn S,Horiba N,Ohtomo S,et al.The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout[J].Ann Rheum Dis,2013,72(Suppl 3):A704 [2015-07-14] .doi: 10.1136/annrheumdis-2013-eular.2081.
    [16]
    Lavan BE,Mcwherter C,Choi YJ.Arhalofenate,a novel uricosuric agent,is an inhibitor of human URIC acid transporters [J].Ann Rheum Dis,2013,71(Suppl 3):450-451.
    [17]
    Steinberg A,Vince B,Choi YJ,et al.A Study to evaluate the pharmacodynamics,pharmacokinetics and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout [J].Ann Rheum Dis,2015,74(Suppl 2):543-544.
    [18]
    Noveck RJ,Wang ZY,Forathoefel A,et al.Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout [J].Arthitis Rheum,2012,64(Suppl 10):818.
    [19]
    Mandal A,Emerling D,Serafini T,et al.Tranilast inhibits urate transport mediated by URAT1 and GLUT9 [J].Arthritis Rheum,2010,62(Suppl 10):164.
    [20]
    Sundy JS,Kitt M,Griffith SG,et al.The combination of tranilast with allopurinol results in enhanced urate-lowering [J].Arthritis Rheum,2010,62(Suppl 10):S67-S68.
    [21]
    Warrell RP,Klukovits A,Barnes K,et al.Novel bifunctional inhibitors of xanthine oxidase and URAT1 induce profound hypouricemiain human subjects [J].Ann Rheum Dis,2014,73(Suppl 2):786.
    [22]
    Richette P,Briere C,Honene CV,et al.Rasburicase for tophaceous gout not treatable with allopurinol:an exploratory study [J].J Rheumatol,2007,34(10):2093-2098.
    [23]
    Sundy JS,Ganson NJ,Kelly SJ,et al.Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout [J].Arthritis Rheum,2007,56(3):1021-1028.
  • Related Articles

    [1]ZHAO Xiaomei, WANG Xin, JI Xia, Zhang Jing, ZHANG Hua, HU Guoqiang. Synthesis and antitumor activity of heteroatom-substituted azulenes derivatives of 1,2-benzothiazine[J]. Journal of China Pharmaceutical University, 2024, 55(5): 634-638. DOI: 10.11665/j.issn.1000-5048.2023120503
    [2]SUN Dongyu, GONG Jingxu, LI Xuwen, HAN Guanying, GUO Yuewei. Studies on methyl xestopongoate analogues:design, synthesis and antitumor activities[J]. Journal of China Pharmaceutical University, 2018, 49(4): 413-421. DOI: 10.11665/j.issn.1000-5048.20180405
    [3]LI Mingtao, XU Dan, XUE Wenjun, YOU Qidong, SUN Liping. Design, synthesis and antitumor activities of oxazolo[5, 4-d]pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(4): 425-431. DOI: 10.11665/j.issn.1000-5048.20170406
    [4]QIAO Yixue, MOU Yi, HUANG Zhangjian, AI Yong, KANG Fenghua, LAI Yisheng, ZHANG Yihua. Synthesis and antitumor activities of novel CDDO-Me analogues[J]. Journal of China Pharmaceutical University, 2015, 46(3): 289-293. DOI: 10.11665/j.issn.1000-5048.20150305
    [5]MAO Chunfang, XU Chenjun, WANG Xuemin, LI Xianghua, ZHANG Wei, WANG Xinyang, LING Yong. Design, synthesis and antitumor activity of farnesylthiosalicylamide derivatives[J]. Journal of China Pharmaceutical University, 2015, 46(2): 162-168. DOI: 10.11665/j.issn.1000-5048.20150204
    [6]HU Kun, ZHOU Anfei, JIANG Hefei, XU Yuanyuan, HUANG Qianhui, YANG Jie, CHEN Xin, REN Jie. Synthesis and antitumor activities of podophyllotoxin derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(1): 33-38. DOI: 10.11665/j.issn.1000-5048.20140105
    [7]CHENG Keguang, CHU Xiangwu, LIU Guanyan, SU Chunhua, DENG Shengping, PAN Hongmei. Synthesis and antitumor activities of 3-substituted estradiol-pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(1): 26-32. DOI: 10.11665/j.issn.1000-5048.20140104
    [8]LIU Dexiu, PAN Huaying, SHI Hui, HUANG Xiaoying, LOU Hongxiang. Synthesis and antitumor activity of a novel bisbibenzyl derivative[J]. Journal of China Pharmaceutical University, 2013, 44(6): 515-519. DOI: 10.11665/j.issn.1000-5048.20130605
    [9]HU Kun, XU Hua-jin, XIN Wen-qun, CHEN Xin, REN Jie. Synthesis and antitumor activity of nitrogen mustard derivatives of formononetin[J]. Journal of China Pharmaceutical University, 2012, 43(2): 113-119.
    [10]ZHA Xiao-ming, ZHANG Fei-ran, SHAN Jia-qi, CHEN Yan-ke, ZHANG Yi-hua, LIU Jun, SUN Hong-bin. Synthesis and in vitro antitumor activities of novel soladulcidine derivatives[J]. Journal of China Pharmaceutical University, 2010, 41(6): 493-498.

Catalog

    Article views (1004) PDF downloads (3988) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return